Elanco Animal Health (NYSE:ELAN – Get Free Report) had its target price hoisted by investment analysts at KeyCorp from $29.00 to $30.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. KeyCorp’s target price points to a potential upside of 36.01% from the company’s current price.
A number of other research analysts have also recently issued reports on the company. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. JPMorgan Chase & Co. upped their price target on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Morgan Stanley raised their target price on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Finally, TD Cowen boosted their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $29.09.
Get Our Latest Stock Analysis on ELAN
Elanco Animal Health Trading Down 8.9%
Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the previous year, the firm posted $0.26 EPS. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts predict that Elanco Animal Health will post 1.12 EPS for the current year.
Insider Buying and Selling
In other news, CEO Jeffrey N. Simmons purchased 4,971 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were purchased at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. This represents a 2.98% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Rajeev A. Modi acquired 4,911 shares of Elanco Animal Health stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, with a total value of $99,938.85. Following the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 1.14% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC lifted its stake in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Elanco Animal Health in the second quarter worth about $38,000. Root Financial Partners LLC raised its position in Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health in the fourth quarter valued at approximately $41,000. Finally, Torren Management LLC purchased a new stake in Elanco Animal Health in the 4th quarter worth approximately $46,000. Institutional investors and hedge funds own 97.48% of the company’s stock.
Elanco Animal Health Company Profile
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
Read More
- Five stocks we like better than Elanco Animal Health
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
